S02.10 · Healthcare & Life Sciences
An extremely concentrated US distribution and PBM chokepoint where AI transparency tools are exposing opaque rebate economics.
Pharmacy, drug distribution and pharmacy benefit management occupy the most concentrated chokepoint in US healthcare. US drug wholesale distribution revenue exceeds $700B (2025E, composite of McKesson, Cencora and Cardinal Health public filings); US PBM-managed drug spend exceeds $500B, though secondary-research market-size figures on the PBM side vary widely and should be treated with caution. No single consolidated figure for the segment is defensible — distribution and benefit management are scoped too differently across sources. The concentration, not the size, is the story.
Growth tracked drug price inflation and volume at 6-8% historically, with 5-7% projected forward. The structure is US-centric and resists international comparison: a three-wholesaler oligopoly paired with a PBM rebate model tied to employer and payer contracts looks nothing like EU distribution, which is more fragmented and margin-regulated. By any sector standard the concentration is extreme — the top 3 wholesalers hold an estimated 90%+ of US distribution, and the top 3 PBMs (CVS Caremark, Express Scripts, OptumRx) hold an estimated 80%+ of covered lives.
Manufacturers sit upstream; retail and specialty pharmacy, payers and patients downstream. The two businesses monetize on opposite models. Distribution is pure logistics economics — low-margin, high-volume, 1-3% operating margin. PBMs earn through rebates and spread pricing, and both mechanisms are under active regulatory and legislative scrutiny: the business model itself is a live policy target, not just individual contract terms.
Claims adjudication, formulary management and rebate reconciliation are being automated, compressing the PBM administrative cost line. That is the small effect. The large one goes to the model's foundation. PBMs have historically monetized opacity in rebate structures, and AI-driven transparency tools now let payers and employers audit spread pricing they previously could not examine economically. A PBM's negotiating leverage has depended in part on counterparties being unable to verify what it actually captures — that opacity-based moat is being dismantled directly, not merely made cheaper to operate. Claims automation is already underway, and regulatory pressure over the next 2-5 years is likely to force business-model restructuring independent of what AI itself does.
Specialty pharmacy expansion chases higher-margin growth in a category less exposed to rebate-transparency regulation than traditional PBM economics — that is where the new dollars sit. Payer/PBM vertical consolidation answers the same transparency pressure defensively: folded into a payer's broader book, individual PBM economics become harder to isolate and regulate. Mail-order and direct-to-consumer distribution is the further adjacency, moving prescriptions to patients outside the traditional retail pharmacy channel.